메뉴 건너뛰기
Journal of Nuclear Cardiology
Volumn 12, Issue 1, 2005, Pages 1-2
Lessons to be learned from the Vioxx debacle

(1)  Beller, George A a  

a NONE
Author keywords

[No Author keywords available]
Indexed keywords

NAPROXEN; PLACEBO; PROSTACYCLIN; ROFECOXIB;
EID: 12744279846     PISSN: 10713581     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nuclcard.2004.11.007     Document Type: Editorial
Times cited : (1)
References (7)
  • 1
    • 6044267892 scopus 로고    scopus 로고
    • Failing the public health - Rofecoxib, Merck, and the FDA
    • E.J. Topol Failing the public health - rofecoxib, Merck, and the FDA N Engl J Med 351 2004 707-1709
    • (2004) N. Engl. J. Med. , vol.351 , pp. 1707-1709
    • Topol, E.J.1
  • 2
    • 9944262983 scopus 로고    scopus 로고
    • Risk of cardiovascular events and rofecoxib: Cumulative meta-analysis
    • (published online 2004 Nov 5). Available from
    • P. Jüni L. Nartay S. Reichenbach R. Sterchi P.A. Dieppe M. Egger Risk of cardiovascular events and rofecoxib : Cumulative meta-analysis 2004 Lancet (published online 2004 Nov 5). Available from http://image.thelancet.com/extras/04art10237web.pdf
    • (2004) Lancet
    • Jüni, P.1    Nartay, L.2    Reichenbach, S.3    Sterchi, R.4    Dieppe, P.A.5    Egger, M.6
  • 3
    • 0034707105 scopus 로고    scopus 로고
    • Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
    • VIGOR study group
    • C. Bombardier L. Laine A. Reicin D. Shapiro R. Burgos-Vargas B. Davis et al. VIGOR study group Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis N Engl J Med 343 2000 1520-1528
    • (2000) N. Engl. J. Med. , vol.343 , pp. 1520-1528
    • Bombardier, C.1    Laine, L.2    Reicin, A.3    Shapiro, D.4    Burgos-Vargas, R.5    Davis, B.6
  • 4
    • 0035934070 scopus 로고    scopus 로고
    • Risk of cardiovascular events associated with selective COX-2 inhibitors
    • D.M. Mukherjee S.E. Nissen E.J. Topol Risk of cardiovascular events associated with selective COX-2 inhibitors JAMA 286 2001 954-959
    • (2001) JAMA , vol.286 , pp. 954-959
    • Mukherjee, D.M.1    Nissen, S.E.2    Topol, E.J.3
  • 5
    • 9944234075 scopus 로고    scopus 로고
    • Vioxx, the implosion of Merck, and aftershocks at the FDA
    • (published online 2004 Nov 5). Available from
    • R. Horton Vioxx, the implosion of Merck, and aftershocks at the FDA 2004 Lancet (published online 2004 Nov 5). Available from http://image.thelancet.com/extras/04cmt396web.pdf
    • (2004) Lancet
    • Horton, R.1
  • 6
    • 0033524421 scopus 로고    scopus 로고
    • Systemic biosynthesis of prostcyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2
    • Erratum in: Proc Natl Acad Sci U S A 1999 65 5890
    • B.F. McAdam F. Catella-Lawson I.A. Mardini S. Kapoor J.A. Lawson G.A. FitzGerald Systemic biosynthesis of prostcyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2 Proc Natl Acad Sci U S A 96 1999 272-277 Erratum in: Proc Natl Acad Sci U S A 1999 65 5890
    • (1999) Proc. Natl. Acad. Sci. U S A , vol.96 , pp. 272-277
    • McAdam, B.F.1    Catella-Lawson, F.2    Mardini, I.A.3    Kapoor, S.4    Lawson, J.A.5    FitzGerald, G.A.6
  • 7
    • 12744252485 scopus 로고    scopus 로고
    • For Merck, defense of a drug crumbles at a difficult time: Earlier trial raised questions of safety
    • Oct. 1;Sect. C
    • B. Meier For Merck, defense of a drug crumbles at a difficult time: earlier trial raised questions of safety 2004 The New York Times Oct. 1;Sect. C:1, 4
    • (2004) The New York Times , vol.1 , pp. 4
    • Meier, B.1

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.